Infectious Disease

2
Pipeline Programs
2
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-7655Phase 15 trials
Active Trials
NCT03969901Completed115Est. May 2024
NCT03583333Completed274Est. Jul 2022
NCT03230916Completed47Est. Aug 2020
+2 more trials
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
1
favipiravirPhase 1Small Molecule1 trial
Active Trials
NCT06024421RecruitingEst. Nov 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Merck & Co.MK-7655
Merck & Co.MK-7655
Merck & Co.MK-7655
FUJIFILM Pharmafavipiravir
Merck & Co.MK-7655
Merck & Co.MK-7655

Clinical Trials (6)

Total enrollment: 1,022 patients across 6 trials

NCT03583333Merck & Co.MK-7655

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Start: Sep 2018Est. completion: Jul 2022274 patients
Phase 3Completed
NCT02493764Merck & Co.MK-7655

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Start: Nov 2015Est. completion: Apr 2019537 patients
Phase 3Completed
NCT03969901Merck & Co.MK-7655

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Start: Oct 2019Est. completion: May 2024115 patients
Phase 2/3Completed
NCT06024421FUJIFILM Pharmafavipiravir

Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Start: May 2024Est. completion: Nov 2027
Phase 1Recruiting
NCT03230916Merck & Co.MK-7655

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Start: Nov 2017Est. completion: Aug 202047 patients
Phase 1Completed
NCT01275170Merck & Co.MK-7655

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Start: Jan 2011Est. completion: Mar 201249 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,022 patients
2 companies competing in this space